Amgen agrees to hand rocatinlimab development back to Kyowa Kirin

In January 2026 Amgen agreed with Kyowa Kirin to terminate their rocatinlimab collaboration, transferring global development and commercialization control to Kyowa Kirin. Amgen said the move follows a portfolio prioritization decision. The change removes a late-stage dermatology program from Amgen's pipeline and reduces its future milestone exposure under the 2021 agreement.

• Agreement to terminate the 2021 rocatinlimab collaboration signed in January 2026
• Kyowa Kirin takes over global development and commercialization
• Termination subject to Hart-Scott-Rodino clearance, which Amgen received in February 2026
• Amgen had been liable for milestone payments of up to $850 million under the original agreement
• Amgen cited strategic portfolio prioritization